The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease
Open accessAbstract
Importance: Previous postmortem studies have long demonstrated that neurofibrillary tangles made of hyperphosphorylated tau proteins are closely associated with Alzheimer disease clinical phenotype and neurodegeneration pattern. Validating these associations in vivo will lead to new diagnostic tools for Alzheimer disease and better understanding of its neurobiology. Objective: To examine whether topographical distribution and severity of hyperphosphorylated tau pathologic findings measured by fluorine 18-labeled AV-1451 ([18F]AV-1451) positron emission tomographic (PET) imaging are linked with clinical phenotype and cortical atrophy in patients with Alzheimer disease. Design, Setting, and Participants: This observational case series, conducted from July 1, 2012, to July 30, 2015, in an outpatient referral center for patients with neurodegenerative diseases, included 6 patients: 3 with typical amnesic Alzheimer disease and 3 with atypical variants (posterior cortical atrophy, logopenic variant primary progressive aphasia, and corticobasal syndrome). Patients underwent [18F]AV-1451 PET imaging to measure tau burden, carbon 11-labeled Pittsburgh Compound B ([11C]PiB) PET imaging to measure amyloid burden, and structural magnetic resonance imaging to measure cortical thickness. Seventy-seven age-matched controls with normal cognitive function also underwent structural magnetic resonance imaging but not tau or amyloid PET imaging. Main Outcomes and Measures: Tau burden, amyloid burden, and cortical thickness. Results: In all 6 patients (3 women and 3 men; mean age 61.8 years), the underlying clinical phenotype was associated with the regional distribution of the [18F]AV-1451 signal. Furthermore, within 68 cortical regions of interest measured from each patient, the magnitude of cortical atrophy was strongly correlated with the magnitude of [18F]AV-1451 binding (3 patients with amnesic Alzheimer disease, r = -0.82; P < .001; r = -0.70; P < .001; r = -0.58; P < .001; and 3 patients with nonamnesic Alzheimer disease, r = -0.51; P < .001; r = -0.63; P < .001; r = -0.70; P < .001), but not of [11C]PiB binding. Conclusions and Relevance: These findings provide further in vivo evidence that distribution of the [18F]AV-1451 signal as seen on results of PET imaging is a valid marker of clinical symptoms and neurodegeneration. By localizing and quantifying hyperphosphorylated tau in vivo, results of tau PET imaging will likely serve as a key biomarker that links a specific type of molecular Alzheimer disease neuropathologic condition with clinically significant neurodegeneration, which will likely catalyze additional efforts to develop disease-modifying therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Thesedistributions are consistentwithBraak stageVneurofibrillary pathologic findings.(23) Closely paralleling [(18)F]AV1451 traceruptake, cortical atrophywasmostprominent in the bilateralmedial temporal, posterior cingulate, precuneus, lateral temporoparietal, andoccipital cortices inall 3patients.”
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894
Self-citationNeurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Self-citationObservations on the brains of demented old people
Tomlinson, B. E., Blessed, G., & Roth, M. (1970) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(70)90063-8 · Cited by 2,084
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“Although fibrillar amyloidplaques are necessary for a pathologic diagnosis of AD,(2) their density and distribution postmortem are weakly associated with clinical features and are not associated with markers of neurodegeneration.(3,4) This finding has been further confirmed in vivo using amyloid positron emission tomo…”
Self-citationQualitative Assessment of Verbal Fluency Performance in Frontotemporal Dementia
van den Berg, E., Jiskoot, L. C., Grosveld, M. J. H., van Swieten, J. C., & Papma, J. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477538 · Cited by 2,046
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
Self-citationLogan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
Self-citationSilverman, D. H. S., Small, G. W., Chang, C. Y., Lu, C. S., de Aburto, M. A. K., Chen, W., Czernin, J., Rapoport, S. I., Pietrini, P., Alexander, G. E., et al. (2001) · JAMA · doi:10.1001/jama.286.17.2120 · Cited by 951
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C., Shankle, W. R., Lerner, A. J., Su, M.-Y., Elizarov, A., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130098 · Cited by 675
Self-citationEarly clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · cited 1×
“The first use of the ligand now known as [(18)F]AV-1451 in patients with AD was reported in 2013.(25) The selectivity of this ligand forhyperphosphorylated tauwas recently confirmed.”
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615
Self-citationGalton, C. J. (2000) · Brain · doi:10.1093/brain/123.3.484 · Cited by 613
Tau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501
Clinical and Pathological Evidence for a Frontal Variant of Alzheimer Disease
Johnson, J. K., Head, E., Kim, R., Starr, A., & Cotman, C. W. (1999) · Archives of Neurology · doi:10.1001/archneur.56.10.1233 · Cited by 415
MRI correlates of neurofibrillary tangle pathology at autopsy: A voxel-based morphometry study
Whitwell, J. L., Josephs, K. A., Murray, M. E., Kantarci, K., Przybelski, S. A., Weigand, S. D., Vemuri, P., Senjem, M. L., Parisi, J. E., Knopman, D. S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324924.91351.7d · Cited by 376
Posterior Cortical Atrophy: Clinical Characteristics and Differences Compared to Alzheimer’s Disease
Mendez, M. F., Ghajarania, M., & Perryman, K. M. (2002) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000058331 · Cited by 363
Amyloid‐β associated cortical thinning in clinically normal elderly
Becker, J. A., Hedden, T., Carmasin, J., Maye, J., Rentz, D. M., Putcha, D., Fischl, B., Greve, D. N., Marshall, G. A., Salloway, S., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22333 · Cited by 342
Self-citationJohnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120618 · Cited by 329
Self-citationDickerson, B. C., Fenstermacher, E., Salat, D. H., Wolk, D. A., Maguire, R. P., Desikan, R., Pacheco, J., Quinn, B. T., Van der Kouwe, A., Greve, D. N., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.08.042 · Cited by 290
Self-citationChanges in premorbid brain volume predict Alzheimer’s disease pathology
Silbert, L. C., Quinn, J. F., Moore, M. M., Corbridge, E., Ball, M. J., Murdoch, G., Sexton, G., & Kaye, J. A. (2003) · Neurology · doi:10.1212/01.wnl.0000079053.77227.14 · Cited by 279
Balit's syndrome in Alzheimer's disease: specific disruption of the occipito-parietal visual pathway
Hof, P. R., Bouras, C., Constandinidis, J., & Morrison, J. H. (1989) · Brain Research · doi:10.1016/0006-8993(89)91173-6 · Cited by 179
Dickerson, B. C., & Wolk, D. A. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00055 · Cited by 172
Self-citationTau, amyloid, and hypometabolism in a patient with posterior cortical atrophy
Ossenkoppele, R., Schonhaut, D. R., Baker, S. L., O’Neil, J. P., Janabi, M., Ghosh, P. M., Santos‐Santos, M., Miller, Z., Bettcher, B. M., Gorno‐Tempini, M. L., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24321 · Cited by 159
Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia
Gefen, T. D., Gasho, K., RADEMAKER, A. W., Lalehzari, M., Weıntraub, S., Rogalski, E. J., Wieneke, C., Bigio, E. H., Geula, C., & Mesulam, M. M. (2012) · Brain · doi:10.1093/brain/aws076 · Cited by 135
Amyloid‐β associated volume loss occurs only in the presence of phospho‐tau
Desikan, R. S., McEvoy, L. K., Thompson, W. K., Holland, D., Roddey, J. C., Blennow, K., Aisen, P. S. S., Brewer, J. B., Hyman, B. T., & Dale, A. M. (2011) · Annals of Neurology · doi:10.1002/ana.22509 · Cited by 129
Self-citationCortical neuroanatomic correlates of symptom severity in primary progressive aphasia
Sapolsky, D., Bakkour, A., Negreira, A. M., Nalipinski, P., Weıntraub, S., Mesulam, M. M., Caplan, D. N., & Dickerson, B. C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ea15e8 · Cited by 120
Self-citationWilson, A. A., García, A., Chestakova, A., Kung, H. F., & Houle, S. (2004) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.854 · Cited by 99
Shining a light on posterior cortical atrophy
Crutch, S. J., Schott, J. M., Rabinovici, G. D., Boeve, B. F., Cappa, S. F., Dickerson, B. C., Dubois, B., Graff‐Radford, N. R., Krolak‐Salmon, P., Lehmann, M., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.11.004 · Cited by 96
Self-citationA concise radiosynthesis of the tau radiopharmaceutical, [18F]T807
Shoup, T. M., Yokell, D. L., Rice, P. A., Jackson, R. N., Livni, E., Johnson, K. A., Brady, T. J., & Vasdev, N. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3098 · Cited by 80
Self-citationAmyloid Imaging in Atypical Presentations of Alzheimer’s Disease
Wolk, D. A. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0412-x · Cited by 58
Amyloid imaging in dementias with atypical presentation
Wolk, D. A., Price, J. C., Madeira, C., Saxton, J. A., Snitz, B. E., López, O. L., Mathis, C. A., Klunk, W. E., & DeKosky, S. T. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.07.003 · Cited by 51
Smith, R. A., Wibom, M., Olsson, T. G., Hägerström, D., Jögi, J., Rabinovici, G. D., & Hansson, O. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151004 · Cited by 30
Tau, amyloid, and hypometabolism in the logopenic variant of primary progressive aphasia
Pascual, B., & Masdeu, J. C. (2016) · Neurology · doi:10.1212/wnl.0000000000002340 · Cited by 15
Cited by
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Hallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789
Imaging the evolution and pathophysiology of Alzheimer disease
Jagust, W. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0067-3 · Cited by 604
Tau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease
Vogel, J. W., Iturria-Medina, Y., Strandberg, O. T., Smith, R., Levitis, E., Evans, A. C., Hansson, O., Initiative, A. D. N., Weiner, M., Aisen, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15701-2 · Cited by 516
Self-citation
Metadata
- Authors
- Xia, C., Makaretz, S. J., Caso, C., McGinnis, S., Gomperts, S. N., Sepulcre, J., Gomez-Isla, T., Hyman, B. T., Schultz, A., Vasdev, N., Johnson, K. A., & Dickerson, B. C.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-04-01
- Volume
- 74
- Issue
- 4
- Pages
- 427
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2590276210
- Cited by
- 282
- References
- 42
- FWCI
- 26.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.